Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00373295 · ClinicalTrials.gov registry record · Phase 2
Effect of Baclofen on Marijuana Withdrawal and Relapse
A Phase 2 study of Marijuana Dependence, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT00373295 is a Phase 2 study of Marijuana Dependence that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 13 participants, below the 90-participant average among 6 other Marijuana Dependence trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00373295, a Phase 2 study of Marijuana Dependence, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Baclofen
- DRUG Marijuana
Study Locations (1)
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2006-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00373295
The ClinicalTrials.gov registry entry for NCT00373295 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 90-participant average among 6 other Marijuana Dependence trials with a reported enrollment target (86% lower). The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Marijuana Dependence appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00373295 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT00373295 about?
NCT00373295 is a clinical study titled "Effect of Baclofen on Marijuana Withdrawal and Relapse". The purpose of this study is to determine if baclofen dose-dependently decreases marijuana's direct effects and symptoms of marijuana withdrawal and thus decreases marijuana relapse.
What is the current status of trial NCT00373295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2006-05. Estimated completion is 2010-01.
What conditions does trial NCT00373295 study?
This clinical trial studies the following conditions: Marijuana Dependence.
What interventions are being tested in trial NCT00373295?
The interventions under investigation include: Placebo (DRUG), Baclofen (DRUG), Marijuana (DRUG).
Who is sponsoring clinical trial NCT00373295?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00373295 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Marijuana Dependence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Vilazodone Treatment for Marijuana Dependence
COMPLETED · Phase 2
-
Effectiveness Study of Dronabinol and BRENDA for the Treatment of Cannabis Withdrawal
COMPLETED · Phase 2
-
Effect of Oxytocin on Craving and Therapy Response
COMPLETED · NA
-
Buspirone Treatment for Marijuana Dependence
COMPLETED · Phase 4
-
Marijuana Treatment Project 4
COMPLETED · NA
-
Effect of Oxytocin on Stress in Marijuana Users
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.